China healthcare stocks sink to record low valuations as capital chases AI

NextFin News - China’s healthcare stocks have slumped to their cheapest level ever. Bloomberg News reported on Tuesday that the CSI Health Care Index is trading at about 2.7 times price to book, below even the low reached during the global financial crisis, as investors pour money into local artificial intelligence winners instead of defensive shares.

The same report said a popular Chinese tech index trades at roughly 8 times book, a gap that captures how sharply capital has rotated. The market is not simply punishing healthcare for weak earnings. It is rewarding anything tied to AI, and that has left drugmakers, hospital operators and medical-device names looking cheap by comparison.

The argument here is based on a single Bloomberg report, not a broad survey of sell-side views. That matters. The piece does not attribute the valuation move to one analyst with a long-running bearish call; it describes a market rotation and a valuation extreme. So the safest reading is that this is a price-and-flow story first, not a consensus judgment that China’s healthcare sector has lost its growth case.

Even so, the gap is hard to ignore. A sector trading below its 2008-09 valuation floor usually tells you investors are demanding a very large discount for each yuan of book value. In practice, that can happen when earnings visibility is poor, policy risk feels sticky, or a hotter theme keeps draining capital. AI is doing the third job here. Domestic beneficiaries are absorbing the bid, and healthcare is paying for it.

What would make the discount narrow? Either healthcare earnings would need to reaccelerate, or the AI trade would need to cool enough for money to search for neglected parts of the market again. Neither is guaranteed. If AI spending keeps pulling attention and liquidity toward a narrow set of Chinese technology names, healthcare may stay cheap even if its fundamentals stop getting worse. If the AI rally loses momentum, the re-rating could come quickly, because valuations are already near a historical extreme.

For now, the market is making a blunt judgment: growth with a story is getting the cash, and defensive health stocks are getting the leftovers.